Filing Details
- Accession Number:
- 0001104659-23-071772
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-06-15 21:00:33
- Reporting Period:
- 2023-06-13
- Accepted Time:
- 2023-06-15 21:00:33
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1737953 | Replimune Group Inc. | REPL | Biological Products, (No Disgnostic Substances) (2836) | 822082553 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1860609 | Sushil Patel | C/O Replimune Group, Inc. 500 Unicorn Park Drive Woburn MA 01801 | Chief Strategy Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2023-06-13 | 5,145 | $24.11 | 149,426 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-06-13 | 553 | $23.44 | 148,873 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 15, 2023, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.
- The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.80 to $24.54. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.29 to $23.53. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- Following the sales reported on this form 4, the reporting person continues to beneficially own 148,873 shares of the Issuer's common stock. The reporting person also holds options to acquire an aggregate of 263,750 shares of the Issuer's common stock, 88,072 of which are exercisable as of the date hereof.
Billionaire Hedge Funds
